Seelos Therapeutics Inc (SEEL)
OTC PINK OTC PINK Primary Summary
Seelos Therapeutics Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 4.12 | $26,080 | $1.53 | -$26,078.47 | -99.99% |
Seelos Therapeutics Inc (SEEL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Seelos Therapeutics Inc ever had a stock split?
Seelos Therapeutics Inc Profile
| Biotechnology Industry | Healthcare Sector | Raj Mehra CEO | OTC PINK Exchange | 81577F208 CUSIP |
| US Country | 8 Employees | - Last Dividend | 27 Sep 2024 Last Split | 19 Apr 1999 IPO Date |
Overview
Seelos Therapeutics, Inc. stands out as a clinical-stage biopharmaceutical company dedicated to advancing therapeutic solutions for a range of conditions, primarily targeting central nervous system, respiratory, and various other disorders. With a commitment to innovation and patient care, Seelos is actively pursuing the development and eventual commercialization of its novel therapeutic candidates. Established in 2016, Seelos operates from its headquarters in New York, New York, where it spearheads research and development efforts to address some of the most challenging medical needs.
Products and Services
- SLS-002:
- SLS-005:
- SLS-006:
- Preclinical Programs:
An intranasal racemic ketamine formulation, SLS-002 is designed for the emergency treatment of acute suicidal ideation and behaviors in major depressive disorder patients. This represents a novel approach to managing crises in psychiatric care, harnessing the unique properties of ketamine.
Focusing on protein stabilization, SLS-005 aims to treat amyotrophic lateral sclerosis (ALS) and Sanfilippo syndrome, offering hope in the fight against these debilitating neurodegenerative diseases. This product underscores the company's commitment to addressing unmet medical needs in the neurology space.
A partial dopamine agonist, SLS-006, is in development for Parkinson's disease patients. Targeting one of the hallmark neurotransmitters affected in Parkinson's disease, this therapeutic approach could offer a new avenue for symptom management and disease progression control.
Seelos is also pursuing several promising preclinical programs, including SLS-007, a peptidic inhibitor aimed at treating Parkinson's disease; SLS-008, targeting pediatric conditions; SLS-004, another Parkinson's disease treatment; SLS-010, an H3 receptor antagonist; and SLS-012. These programs represent the company's forward-thinking strategy and dedication to expanding its portfolio to include innovative treatments for complex diseases.
